{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:02:21Z","timestamp":1790017341200,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.intimp.2023.109952","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T12:35:06Z","timestamp":1677846906000},"page":"109952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Thymosin alpha 1 \u2013 Reimagine its broader applications in the immuno-oncology era"],"prefix":"10.1016","volume":"117","author":[{"given":"Li","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.intimp.2023.109952_b0005","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2006-02-004762","article-title":"Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance","volume":"108","author":"Romani","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.intimp.2023.109952_b0010","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1196\/annals.1415.002","article-title":"Thymsoin alpha 1: an endogenous regulator of inflammation, immunity, and tolerance","volume":"1112","author":"Romani","year":"2007","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2023.109952_b0015","doi-asserted-by":"crossref","unstructured":"Romani L, Moretti S, Fallarino F, Bozza S, Ruggeri L, Casagrande A, Aversa F, Bistoni F, Velardi A, Garaci E. Jack of all trades: thymosin alpha 1 and its pleiotropy. Ann. N.Y. Acad. Sci. 2012; 1269-1270:5-10.","DOI":"10.1111\/j.1749-6632.2012.06716.x"},{"key":"10.1016\/j.intimp.2023.109952_b0020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMra021333","article-title":"The pathophysiology and treatment of sepsis","volume":"348","author":"Hotchkiss","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109952_b0025","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/cc10452","article-title":"Commentary: a dynamic view of mHLA-DR expression in management of severe septic patients","volume":"15","author":"Monneret","year":"2011","journal-title":"Critical Care"},{"issue":"10","key":"10.1016\/j.intimp.2023.109952_b0030","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.2009.25.5208","article-title":"Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma","volume":"28","author":"Maio","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109952_b0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00008390-200010020-00012","article-title":"Combined treatment with thymosin alpha 1 and low-dose interferon alpha after dacarbazine in advanced melanoma","volume":"10","author":"Rasi","year":"2000","journal-title":"Melanoma Res."},{"key":"10.1016\/j.intimp.2023.109952_b0040","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/oxfordjournals.annonc.a058979","article-title":"Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects","volume":"5","author":"Lopez","year":"1994","journal-title":"Annals Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109952_b0045","first-page":"147","article-title":"A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer","volume":"4","author":"Schulof","year":"1985","journal-title":"J. Biol. Response Mod."},{"issue":"3","key":"10.1016\/j.intimp.2023.109952_b0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijrobp.2022.07.009","article-title":"Efficacy of Thymosin \u03b11 in management of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy: a phase 2 Clinical Trial (GASTO-1043)","volume":"114","author":"Liu","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"22","key":"10.1016\/j.intimp.2023.109952_b0055","first-page":"756","article-title":"Impact of thymosin a1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis","volume":"134","author":"Guo","year":"2021","journal-title":"Chin Med J (Engl)."},{"key":"10.1016\/j.intimp.2023.109952_b0060","first-page":"20","article-title":"Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma A propensity score matching analysis","volume":"100","author":"He","year":"2021","journal-title":"Medicine"},{"issue":"14","key":"10.1016\/j.intimp.2023.109952_b0065","first-page":"77","article-title":"The use of thymosin alpha 1 in advanced non-small cell lung cancer treatment","volume":"46","author":"Ma","year":"2006","journal-title":"Shangdong Pharmaceutical"},{"key":"10.1016\/j.intimp.2023.109952_b0070","unstructured":"Sun X, Gao F, Liu X, Li G. The influence of thymosin alpha 1 on cellular immune function during chemotherapy for non-small cell lung cancer patients. Shangdong Medical Journal (2009) 49(31):83-83."},{"issue":"10","key":"10.1016\/j.intimp.2023.109952_b0075","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1158\/0008-5472.CAN-21-4260","article-title":"Thymosin \u03b1-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis","volume":"82","author":"Wei","year":"2022","journal-title":"Cancer Res."},{"issue":"7776","key":"10.1016\/j.intimp.2023.109952_b0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","article-title":"Harnessing innate immunity in cancer therapy","volume":"574","author":"Demaria","year":"2019","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.intimp.2023.109952_b0085","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance Mechanisms of Anti-PD1\/PDL1 Therapy in Solid Tumors","volume":"21","author":"Lei","year":"2020","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.intimp.2023.109952_b0090","doi-asserted-by":"crossref","unstructured":"Immune Checkpoint Inhibitor Toxicities; Mayo Clinic Proceedings, Concise review for clinicians, volume 94, issue 7, P1321-1329, Jul 01, 2019.","DOI":"10.1016\/j.mayocp.2019.03.012"},{"issue":"7","key":"10.1016\/j.intimp.2023.109952_b0095","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","article-title":"Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape","volume":"21","author":"Upadhaya","year":"2022","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.intimp.2023.109952_b0100","unstructured":"BMS-Nektar press release, 14 March 2022: https:\/\/news.bms.com\/news\/corporate-financial\/2022\/Bristol-Myers-Squibb-andNektar-Announce-Update-on-Phase-3-PIVOT-IO-001-Trial-Evaluating-Bempegaldesleukin-BEMPEG-in-Combination-withOpdivo-nivolumab-in-Previously-Untreated-Unresectable-or-Metastatic-Melanoma\/default.aspx."},{"key":"10.1016\/j.intimp.2023.109952_b0105","unstructured":"Roche\u2019s Tecentriq combination fails in Phase III breast cancer trial, 7 August 2020: https:\/\/www.clinicaltrialsarena.com\/news\/roche-tecentriq-breast-cancer-data."},{"key":"10.1016\/j.intimp.2023.109952_b0110","unstructured":"Acalabrutinib Plus Pembrolizumab Failed to Improve Outcomes in Relapsed mUC, 17 August 2020: https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/bladder-cancer\/urothelial-cancer-acalabrutinib-pembrolizumab-failedimprove-outcomes."},{"key":"10.1016\/j.intimp.2023.109952_b0115","unstructured":"Merck press release, 15 March 2022: https:\/\/www.merck.com\/news\/merck-announces-keylynk-010-trial-evaluating-keytrudapembrolizumab-in-combination-with-lynparza-olaparib-in-patients-with-metastatic-castration-resistant-prostate-cancer-tostop."},{"key":"10.1016\/j.intimp.2023.109952_b0120","unstructured":"AstraZeneca Imfinzi combination fails advanced lung cancer study, 21 Aug 2019: https:\/\/www.reuters.com\/article\/usastrazeneca-imfinzi-trial."},{"issue":"5","key":"10.1016\/j.intimp.2023.109952_b0125","first-page":"67","article-title":"Thymosin alpha 1: A comprehensive review of the literature. World","volume":"9","author":"Dominari","year":"2020","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.intimp.2023.109952_b0130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/intimm\/dxac013","article-title":"A variety of 'exhausted' T cells in the tumor microenvironment","volume":"34","author":"Nagasaki","year":"2022","journal-title":"Int Immunol."},{"key":"10.1016\/j.intimp.2023.109952_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2010.05465.x","article-title":"Thymosin \u03b11: the regulator of regulators?","author":"Pierluigi","year":"2010","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2023.109952_b0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/14712598.2018.1494717","article-title":"Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy","volume":"18","author":"Danielli","year":"2018","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.intimp.2023.109952_b0145","doi-asserted-by":"crossref","unstructured":"Bo C, Wu Q, Zhao H, Li X, Zhou Q. Thymosin alpha1 suppresses migration and invasion of PD-L1 high-expressing non-small-cell lung cancer cells via inhibition of STAT3-MMP2 signaling. Onco Targets Ther. (2018) 11:7255\u201370.","DOI":"10.2147\/OTT.S177943"},{"issue":"10","key":"10.1016\/j.intimp.2023.109952_b0150","doi-asserted-by":"crossref","first-page":"e202000662","DOI":"10.26508\/lsa.202000662","article-title":"Thymosin \u03b11 protects from CTLA-4 intestinal immunopathology","volume":"3","author":"Renga","year":"2020","journal-title":"Life Sci Alliance."},{"key":"10.1016\/j.intimp.2023.109952_b0155","doi-asserted-by":"crossref","unstructured":"ntonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpe\u00f1o J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, \u00d6zg\u00fcro\u011flu M; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017;377:1919\u20131929.","DOI":"10.1056\/NEJMoa1709937"},{"key":"10.1016\/j.intimp.2023.109952_b0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2021.01.022","article-title":"Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy","volume":"151","author":"Friedes","year":"2021","journal-title":"Lung Cancer"},{"issue":"18","key":"10.1016\/j.intimp.2023.109952_b0165","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1002\/cam4.3306","article-title":"Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study","volume":"9","author":"Horinouchi","year":"2020","journal-title":"Cancer Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:04:01Z","timestamp":1761588241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923002722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":33,"alternative-id":["S1567576923002722"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109952","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymosin alpha 1 \u2013 Reimagine its broader applications in the immuno-oncology era","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109952"}}